Skip to main content
Erschienen in: International Journal of Hematology 6/2020

25.07.2020 | Case Report

A family with an MYH9-related disorder with different phenotypes masquerading as immune thrombocytopaenia: an underreported disorder in Taiwan

verfasst von: Ying-Chih Huang, Yu-Hung Shih, Ching-Yeh Lin, Ping-Fang Chiu, Su-Feng Kuo, Jen-Shiou Lin, Ming-Ching Shen

Erschienen in: International Journal of Hematology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

A 66-year-old woman had experienced abnormal bleeding since the age of 7. Thrombocytopenia was not detected until she was 48, and immune thrombocytopenia was diagnosed at age 66. She also reported experiencing hearing disturbance since the age of 30 and acute renal failure since the age of 61 but reported no visual disturbance. Her younger son, who was 40 years old, also experienced abnormal bleeding since the age of 6, but immune thrombocytopenia was diagnosed as late as age 35. He had no other associated disorders. Laboratory examinations of both mother and son revealed a low platelet count (8000 and 29,000 µL, respectively), giant platelets and Döhle body-like granulocyte inclusion bodies. The mother had a high creatinine level (15.4 mg/dL) and normal liver enzyme levels. MYH9 genetic analysis identified a heterozygous mutation, c.101T>A, p.Val34Glu at exon 2 in both patients. These clinical and laboratory findings were consistent with a diagnosis of an MYH9-related disorder with different phenotypes observed in the same family. MYH9-related disorders were recognised in 2003, but were often misdiagnosed as immune thrombocytopenia, and hence, they have rarely been reported in Taiwan.
Literatur
1.
Zurück zum Zitat Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, et al. MYH9-related disease: May–Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82(3):203–15. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, et al. MYH9-related disease: May–Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82(3):203–15.
2.
Zurück zum Zitat Sellers JR. Myosins: a divserse superfamily. Biochim Biophys Acta. 2000;1496(1):3–22.CrossRef Sellers JR. Myosins: a divserse superfamily. Biochim Biophys Acta. 2000;1496(1):3–22.CrossRef
3.
Zurück zum Zitat Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Haemost. 2009;35(2):189–203.CrossRef Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Haemost. 2009;35(2):189–203.CrossRef
4.
Zurück zum Zitat Toothaker LE, Gonzalez DA, Tung N, Lemons RS, Le Beau MM, Arnaout MA, et al. Cellular myosin heavy chain in human leukocytes: isolation of 5′ cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation. Blood. 1991;78(7):1826–33.CrossRef Toothaker LE, Gonzalez DA, Tung N, Lemons RS, Le Beau MM, Arnaout MA, et al. Cellular myosin heavy chain in human leukocytes: isolation of 5′ cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation. Blood. 1991;78(7):1826–33.CrossRef
5.
Zurück zum Zitat Kunishima S, Kojima T, Tanaka T, Kamiya T, Ozawa K, Nakamura Y, et al. Mapping of a gene for May–Hegglin anomaly to chromosome 22q. Hum Genet. 1999;105(5):379–83.CrossRef Kunishima S, Kojima T, Tanaka T, Kamiya T, Ozawa K, Nakamura Y, et al. Mapping of a gene for May–Hegglin anomaly to chromosome 22q. Hum Genet. 1999;105(5):379–83.CrossRef
6.
Zurück zum Zitat Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. Mutation in MYH9 result in the May–Hegglin, anomaly and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet. 2000;26(1):103–5.CrossRef Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. Mutation in MYH9 result in the May–Hegglin, anomaly and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet. 2000;26(1):103–5.CrossRef
7.
Zurück zum Zitat Hodge T, Cope MJ. A myosin family tree. J Cell Sci. 2000;113(19):3353–4.PubMed Hodge T, Cope MJ. A myosin family tree. J Cell Sci. 2000;113(19):3353–4.PubMed
8.
Zurück zum Zitat Althaus K, Greinacher A. MYH-9 related platelet disorders: strategies for management and diagnosis. Transfus Med Hemother. 2010;37(5):260–7.CrossRef Althaus K, Greinacher A. MYH-9 related platelet disorders: strategies for management and diagnosis. Transfus Med Hemother. 2010;37(5):260–7.CrossRef
9.
Zurück zum Zitat Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10(11):778–90.CrossRef Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol. 2009;10(11):778–90.CrossRef
10.
Zurück zum Zitat Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May–Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-Like syndromes. Am J Hum Genet. 2001;69(5):1033–45.CrossRef Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May–Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-Like syndromes. Am J Hum Genet. 2001;69(5):1033–45.CrossRef
11.
Zurück zum Zitat Seri M, Savino M, Bordo D, Cusano R, Rocca B, Meloni I, et al. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet. 2002;110(2):182–6.CrossRef Seri M, Savino M, Bordo D, Cusano R, Rocca B, Meloni I, et al. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet. 2002;110(2):182–6.CrossRef
12.
Zurück zum Zitat Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF, et al. Mutation spectrum and genotype–phenotype correlations in a large French cohort of MYH9-related disorders. Mol Genet Genomic Med. 2014;2(4):297–312.CrossRef Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF, et al. Mutation spectrum and genotype–phenotype correlations in a large French cohort of MYH9-related disorders. Mol Genet Genomic Med. 2014;2(4):297–312.CrossRef
13.
Zurück zum Zitat Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat. 2008;29(3):409–17.CrossRef Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat. 2008;29(3):409–17.CrossRef
14.
Zurück zum Zitat Lin JS, Shen MC, Wang CH, Lin CT. Familial macrothrombocytopenia with granulocyte inclusion: a clinical and laboratory problem. J Formos Med Assoc. 1998;97(2):118–22.PubMed Lin JS, Shen MC, Wang CH, Lin CT. Familial macrothrombocytopenia with granulocyte inclusion: a clinical and laboratory problem. J Formos Med Assoc. 1998;97(2):118–22.PubMed
15.
Zurück zum Zitat Sung CC, Lin SH, Chao TK, Chen YC. R1933X mutation in the MYH9 gene in May–Hegglin anomaly mimicking idiopathic thrombocytopenic purpura. J Formos Med Assoc. 2014;113(1):56–9.CrossRef Sung CC, Lin SH, Chao TK, Chen YC. R1933X mutation in the MYH9 gene in May–Hegglin anomaly mimicking idiopathic thrombocytopenic purpura. J Formos Med Assoc. 2014;113(1):56–9.CrossRef
16.
Zurück zum Zitat Chang TH, Hwang DY, Chiou PF, Wu CL, Lin CH, Kuo SF, et al. Novel identification of a sporadic MYH9-related disease with Uremia in Taiwanese: a case report and literature review. Acta Nephrolog. 2017;31(1):26–30. Chang TH, Hwang DY, Chiou PF, Wu CL, Lin CH, Kuo SF, et al. Novel identification of a sporadic MYH9-related disease with Uremia in Taiwanese: a case report and literature review. Acta Nephrolog. 2017;31(1):26–30.
17.
Zurück zum Zitat Toren A, Rozenfeld-Granot G, Rocca B, Epstein CJ, Amariglio N, Laghi F, et al. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood. 2000;96(10):3447–511.CrossRef Toren A, Rozenfeld-Granot G, Rocca B, Epstein CJ, Amariglio N, Laghi F, et al. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood. 2000;96(10):3447–511.CrossRef
18.
Zurück zum Zitat Kunishima S, Kojima T, Matsushita T, Tanaka T, Tsurusawa M, Furukawa Y, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May–Hegglin anomaly/Sebastian syndrome). Blood. 2001;97(4):1147–9.CrossRef Kunishima S, Kojima T, Matsushita T, Tanaka T, Tsurusawa M, Furukawa Y, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May–Hegglin anomaly/Sebastian syndrome). Blood. 2001;97(4):1147–9.CrossRef
19.
Zurück zum Zitat Pujol-Moix N, Kelly MJ, Hernandez A, Muniz-Diaz E, Espanol I. Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9 related disorders. Haematologica. 2004;89(3):330–7.PubMed Pujol-Moix N, Kelly MJ, Hernandez A, Muniz-Diaz E, Espanol I. Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9 related disorders. Haematologica. 2004;89(3):330–7.PubMed
20.
Zurück zum Zitat Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C, et al. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum mol Genet. 2005;14(21):3169–78.CrossRef Pecci A, Canobbio I, Balduini A, Stefanini L, Cisterna B, Marseglia C, et al. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum mol Genet. 2005;14(21):3169–78.CrossRef
21.
Zurück zum Zitat Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, et al. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype–phenotype correlations. Hum Mutat. 2014;35(2):236–47.CrossRef Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, et al. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype–phenotype correlations. Hum Mutat. 2014;35(2):236–47.CrossRef
22.
Zurück zum Zitat Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011;154(2):161–74.CrossRef Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011;154(2):161–74.CrossRef
23.
Zurück zum Zitat Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med. 2007;131(12):1834–6.PubMed Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med. 2007;131(12):1834–6.PubMed
24.
Zurück zum Zitat Köhler M, Hellstern P, Morgenstern E, Mueller-Eckhardt C, Berberich R, Meiser RJ, et al. Gray platelet syndrome: selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover. Blut. 1985;50(6):331–40.CrossRef Köhler M, Hellstern P, Morgenstern E, Mueller-Eckhardt C, Berberich R, Meiser RJ, et al. Gray platelet syndrome: selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover. Blut. 1985;50(6):331–40.CrossRef
25.
Zurück zum Zitat Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of novel GATA1 mutation. Blood. 2001;98(1):85–92.CrossRef Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of novel GATA1 mutation. Blood. 2001;98(1):85–92.CrossRef
26.
Zurück zum Zitat Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, UKHCDO, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603–33.CrossRef Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, UKHCDO, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603–33.CrossRef
Metadaten
Titel
A family with an MYH9-related disorder with different phenotypes masquerading as immune thrombocytopaenia: an underreported disorder in Taiwan
verfasst von
Ying-Chih Huang
Yu-Hung Shih
Ching-Yeh Lin
Ping-Fang Chiu
Su-Feng Kuo
Jen-Shiou Lin
Ming-Ching Shen
Publikationsdatum
25.07.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 6/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02947-1

Weitere Artikel der Ausgabe 6/2020

International Journal of Hematology 6/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.